p e r s p e c t i v e
Autism spectrum disorder (ASD) encompasses a range of disorders that are characterized by social and communication deficits and repetitive behaviors. For the majority of affected individuals, the cause of ASD remains unknown, but in at least 20% of the cases, a genetic cause can be identified. There is currently no cure for ASD; however, results from mouse models indicate that some forms of the disorder could be alleviated even at the adult stage. Genes involved in ASD seem to converge on common pathways altering synaptic homeostasis. We propose, given the clinical heterogeneity of ASD, that specific 'synaptic clinical trials' should be designed and launched with the aim of establishing whether phenotype 'reversals' could also occur in humans.
ASD comprises a heterogeneous group of disorders with different etiologies, phenotypic outcomes and ages of onset. In a subset of patients with ASD, mutations of genes related to synaptic function have been identified, suggesting that abnormal neuronal homeostasis is a risk factor for ASD 1, 2 . Studies of the human brain transcriptome have shown that genes associated with synaptic functions may be expressed early during intrauterine development (3-6 months gestational age) 3 . However, the consequences of these alterations in gene expression are only detected as ASD much later, during the first 3 years of life. It is not known whether neuronal circuits expressing these genes can be preserved despite the presence of genetic mutations. An increasing number of studies in mouse models of ASD have shown that certain neuronal defects can be reversed in the mature mouse brain, either by restoring the gene function, decreasing mRNA translation or modulating the balance between excitation and inhibition ( Table 1 and  Supplementary Table 1) . These results challenge the notion that all forms of ASD are irreversible neurodevelopmental disorders 4 . Given the clinical heterogeneity of ASD, we argue that specific synaptic clinical trials should be designed and launched with a view to establishing whether or not similar reversals could also occur in humans.
The clinical trajectory and heterogeneity of ASD The very early (premorbid) signs of ASD are still largely unknown, which brings into question whether reversibility is possible and whether there might be a discrete window for reversing the pathological process. Among clinicians, there is agreement that autistic symptoms are relatively stable over time 5 . Nevertheless, over the past decades, several reports have described individuals with autism who were clearly affected in early childhood but emerged as adolescents and adults with relatively ordinary lives and no profound behavioral deficits. In a recent prospective study of 6,975 children with ASD followed from diagnosis through age 14, six distinct common trajectories of social, communication and repetitive behavior were identified 6 . For example, 21.4% of the subjects never showed repetitive behaviors, and 8.1% presented with repetitive behaviors at age 3 but improved as they grew older (Fig. 1) . Most of the trajectories remained stable from 4 to 14 years, but with different levels of severity. Interestingly, about one in ten children with ASD experienced rapid gains in communication and social abilities, moving from severely affected to high functioning ('bloomers').
The core symptoms of ASD are rarely seen in isolation and usually coexist with other psychiatric and medical conditions, including intellectual disability, language disorders, epilepsy, motor control problems, attention-deficit/hyperactivity disorders, tics, anxiety, sleep disorders, gastrointestinal problems and abnormal (too high or too low) response to sensory stimuli. Intensive behavioral interventions have been shown to improve the cognitive and adaptive behaviors of young children with ASD 7 . However, treatments for ASD need to take into account the extreme degree of etiological and clinical heterogeneity of these conditions and also the possibility that multiple treatments might be needed to target different types of symptoms. The concept of ESSENCE (early symptomatic syndromes eliciting neurodevelopmental clinical examinations) was recently introduced to better take into account the clinical heterogeneity and syndromatic overlap of developmental symptoms that impair children under the age of 3-5 years 8 .
The relationship between brain development and function Neuronal circuits are shaped by genes and the environment throughout life, but there are some critical periods when brain development is particularly sensitive to experience 9 . During early life, these key periods of high brain plasticity involve sensory systems, but also motor functions and cognition 10 . After these 'windows in development' , the level of plasticity is reduced 9, 11 . This reduced plasticity is linked to the development of myelin or perineuronal networks that drastically curtail neurite outgrowth in the mature brain and also to functional modifications in the excitation-inhibition balance 9, 11 . For example, local GABAergic circuits modulate visual cortical plasticity in early postnatal life 9 , and similar fine-tuning of excitation and inhibition is also crucial for correct auditory cortical development 12 . Autism was proposed as a critical-period disorder 13 after it was shown that mutations in several genes associated with ASD may affect the early inhibition-excitation balance, thus shifting the timing of critical periods or even completely obliterating such periods of high neuronal plasticity. Dysfunction in auditory, visual and somatosensory information processing might even be the primary factor driving aberrant development of socialization and communication skills in ASD 13 . Thus, if a gene is required at a specific developmental stage, its reactivation at a later stage outside the critical period might be insufficient to reverse the consequence of its early loss. Genetic studies have identified hundreds of genes associated with ASD 2,14,15 . These genes have roles in various physiological processes, such as chromatin remodeling, metabolism, translation and synaptogenesis. It is speculated, however, that these genes may converge into pathways affecting distinct neuronal functions 2 . Neuronal and/or synaptic homeostasis could be one of these functions, which would help explain why opposite morphological or functional defects in ASD sometimes lead to similar clinical outcomes 16, 17 . For example, a reduction in the number of dendrites was observed in Rett and tuberous sclerosis syndromes, whereas a high density of dendrites was reported in fragile X syndrome 16 . These three genetic syndromes have a very high rate of associated ASD symptoms (up to 60% of affected individuals for fragile X and Rett syndromes, and up to 50% of individuals with tuberous sclerosis syndrome). Similarly, some mutations increase or reduce excitatory currents, whereas some increase or decrease inhibitory currents. For example, Shank3 (encoding SH3 and multiple npg p e r s p e c t i v e ankyrin-repeat domains 3) homozygous-knockout mice show a reduction in the frequency and amplitude of their excitatory postsynaptic currents 18 , whereas Nlgn3 (encoding neuroligin 3) knock-in R451C mice show an increase in the frequency of their inhibitory post-synaptic currents 19 . Interestingly, several genes associated with ASD are modulated by neuronal activity 20 , suggesting that they may mediate experiencedependent circuit modifications 2 . For example, a subset of genes associated with ASD (such as NLGN3, NRXN1 (encoding neurexin 1), SHANK3, PTEN (encoding phosphatase and tensin homolog), TSC2 (encoding tuberous sclerosis 2) and NF1 (encoding neurofibromin 1)) are targets of the fragile X mental retardation protein (FMRP, encoded by FMR1) responsible for fragile X syndrome and regulation of neuronal translation 21 .
It remains largely unknown in which phases of development mutations found in ASD produce a detectable phenotype. In rodents, most genes involved in synaptogenesis are strongly expressed after birth and reach a plateau in adulthood [22] [23] [24] . In contrast, in humans, the genes involved in dendrite and synapse formation are switched on very early in utero, and the amounts of transcripts reach a plateau at 6-9 months of fetal life 3 . This may also be the case for most ASD susceptibility genes. But, even if these genes are expressed at a very early stage of brain development, the impact of their mutation on brain function seems to be delayed and only observable at a later stage (Fig. 1) . This delay between the initial expression of the gene and the functional impact of the mutation might have several different causes.
First, genetic redundancy might occur at early stages of development. Mutations usually affect a single allele of a gene, and the mutated gene may belong to a family of genes (for example, the SHANK family). Thus, the second allele, or other members of the same gene family (for example, SHANK1, SHANK2 and SHANK3) might preserve the gene's functions early on, but its late functions cannot be compensated. In such a case, the basic wiring of the brain might not be affected. Such compensation and functional redundancy of synaptic proteins during development has been observed, for example, in mice lacking the synaptic scaffolding protein DLG1 (also known as SAP97) 25 .
Second, the functional consequences of the mutations may only be detectable when the networks are fully mature (that is, in postnatal life, at an early stage of development). In this case, defects in cellular differentiation, cellular migration or long-distance axon guidance might be detected only when a specific ability, such as spoken language, develops. Among the proteins associated with ASD that could affect neuronal connectivity are the contactins, the semaphorins and the SHANK proteins. Contactins and semaphorins are directly involved in neuritogenesis and axon guidance, but they are also found at the synapse. SHANK3 is important for dendrite formation but is also abundant in the growth cone of axons during migration, suggesting that it may also be necessary for long-distance connectivity 26 . In this case, the mutations might affect the hard wiring of neuronal networks, and recovery from an ASD after the brain has fully matured might be more difficult to achieve. This was recently shown for an inducible mouse model lacking SYNGAP1, a synaptic protein crucial for dendritic spine development. Inducing SYNGAP1 mutations after the critical period of spine development did not adversely affect spines; however, if the mutation was induced during the critical period, repair of the synaptic defect in adulthood did not improve the aberrant behavioral phenotypes 27 .
Third, the apparent delay between gene expression and phenotypic outcome might also be a result of the challenge of detecting early phenotypic features, for example, during pregnancy. After birth, most children with ASD experience a decline in the acquisition of developmental milestones from 6 to 36 months 28 , with less pointing by 12 months, fewer communicative gestures and responses to name by 18 months and less eye contact by 24 months (Fig. 1) . Differences in patterns of head growth 29 and aberrant white matter organization 30 have occurred in some cases during the first year of life, and differences in event-related potential to face processing 31 and in electroencephalographic activity 32 have been detected at as early as 6-10 months of age. These features are not specific to ASD but might be early signs of abnormal synaptic homeostasis and of a variety of neurodevelopmental dysfunctions.
To obtain the proof of principle for reversion of a specific neuronal defect, mouse models carrying similar mutations to those identified in individuals with ASD have been generated that allow the mutated genes to be conditionally reactivated in the mature brain. Such mice can be used to test the potential for reversibility, but species-specific differences might limit direct predictions in humans, and thus results from clinical trials are required to provide reliable information about the possibility of alleviating the disorder.
From mice to humans: developing treatments for ASD Numerous studies have investigated the possibility of treating the phenotype in mouse models of fragile X syndrome and Rett syndrome as well in mice containing mutations of synaptic proteins associated with ASD ( Table 1 and Supplementary Table 1 ). Strategies to alleviate the abnormal phenotype include genetic manipulation and cellular therapy, pharmacological intervention and environmental stimulation. Most studies have first focused on the comorbidities observed in mouse models of ASD, such as presence of seizures, abnormal locomotor activity and anxiety 4, 33, 34 . Recent studies have undertaken a more comprehensive behavioral characterization of the core symptoms of ASD by exploring, for example, social interactions or ultrasonic vocalizations as a possible paradigm for speech deficiency 35, 36 .
Genetic and cellular therapeutic strategies. Experiments using genetic interactions (crossing mouse strains that carry mutations in different genes) have been used to modulate the expression of the genes and pathways of interest in ASD. In the fragile X model lacking the Fmr1 gene, expression of a functional human FMR1 gene restored social behavior and sensory gating [37] [38] [39] . Interestingly, overexpression of neuroligin 1, a synaptic cell adhesion molecule mutated in some cases of ASD 40 , can also improve social behavior in fragile X model mice but has no positive effect on learning or memory 41 . Similar experiments have been performed to compensate for the downstream effects of mutations: excessive mRNA translation following mGluR5 signaling, overexpression of amyloid-β protein or overexpression of the striatal-enriched protein tyrosine phosphatase in the fragile X mouse model [42] [43] [44] and reduced expression of brain-derived neurotrophic factor (BDNF) in the Rett syndrome mouse model 45 . These studies have achieved partial improvements: reduction in the number of seizures, reduction of body weight, decreased gait abnormalities, improved locomotor activity and reduced social and nonsocial anxiety ( Table 1) . Crossing mouse lines, however, provides no information on the reversibility of the phenotype in adult mice, as the compensation occurs from an early stage of development.
Genetic manipulation and cellular therapy strategies have also been used to reverse neuroanatomical and behavioral abnormalities in mice modeling ASD. In a pioneering experiment, the group of Adrian Bird created a mouse model of Rett syndrome in which the endogenous Mecp2 gene (encoding methyl CpG-binding protein 2) was silenced but could be conditionally activated 4 . They showed that npg p e r s p e c t i v e nature medicine VOLUME 19 | NUMBER 6 | JUNE 2013activation of Mecp2 in 70% of neurons in both immature and mature adult mice reversed many morphological defects in the motor cortex, including neuronal size and dendritic complexity. This led to a marked improvement in respiratory and sensorimotor functions, including breathing pattern, grip strength and balance-beam and rotarod performance 4 . In a follow-up study, reexpression of Mecp2 only in catecholaminergic cells was sufficient to improve survival, general activity, motor coordination and seizure-like cortical activity in Mecp2 +/− mice 46 . Recently, Derecki et al. 47 used transplantation of wild-type bone marrow to introduce microglial cells into the Mecp2 knockout mouse model of Rett syndrome. This resulted in increased lifespan, normalization of breathing patterns, reduction of apnea, normalization of body weight and improved locomotor activity in these mice 47 . Taken together, these findings support the view that MECP2 does not necessarily play a pivotal part in brain development but may instead be required to maintain full neurological function once development has occurred 4 .
Pharmacological therapeutic strategies. Pharmacological interventions for ASD have been facilitated by the fact that most of the molecules tested in mice have already been used in humans for other purposes (for example, ampakine (CX546), dicyclomine, minocycline, desipramine, d-cycloserine, fingolimod). Lifespan, seizure, learning, memory and anxiety have been shown to be robustly ameliorated by pharmacological treatments [48] [49] [50] [51] [52] [53] . In a recent study on BTBR T+tf/J mice, a partial improvement of social interest was even possible with treatment with ampakine, a positive modulator of AMPA receptors, acting to enhance glutamatergic neurotransmission 36 . However, treatment of ASD core symptoms-decreased social interaction and increased stereotypy-may be more challenging. For example, in Figure 2 The synaptic proteins involved in ASD and the drugs that have been tested in mouse models of ASD or in clinical trials. Schematic representation of pre-and post-synaptic proteins located at glutamatergic and GABAergic synapses. Proteins reported to be associated with ASD are in orange. Factors involved in the pathways that the ASD-associated proteins participate in are shown in blue. Pharmacological compounds used to reverse core symptoms of autism in mouse models and patients are tagged with a star. The functional link between these proteins were shown experimentally (for example: FMRP targets distinct mRNA sequence elements to regulate expression of several proteins associated with ASD 109 and eIF4E overexpression leads to increased translation of neuroligins 110 , which are postsynaptic proteins that are causally linked to ASDs 111 ). The pathways associated with ASD are reviewed in refs. 2,56,112. npg p e r s p e c t i v e 6 9 0 VOLUME 19 | NUMBER 6 | JUNE 2013 nature medicine Cntnap2 knockout mice, risperidone can alleviate increased repetitive behavior, but not social deficits 54 , a dissociation similar to what is seen in humans treated with the same drug 55 . Empirical treatments that target two pathways in ASD (mRNA translation and excitation-inhibition balance) are now emerging and have shown some promise (Fig. 2) . The possibility that targeting mRNA translation in ASD might be therapeutically beneficial was suggested by reports of aberrant mRNA translation of synaptic proteins in people with ASD 56 . The evidence supporting this theory includes the identification of mutations affecting several proteins (NF1, TSC1, TSC2 and PTEN) that normally inhibit mRNA translation through the phosphoinositide 3-kinase-mammalian target of rapamycin (PI3K-mTOR) signaling pathway or in proteins directly involved in the inhibition of mRNA translation at the synapse (FMR1, CYFIP1 and ELF4E) in patients with ASD [57] [58] [59] [60] . In addition, an excess of mRNA translation (20%) was observed in the Fmr1 knockout mouse model of fragile X syndrome. On the basis of these findings, two main strategies have been used to inhibit translation in mouse models of ASD.
The first strategy is repression of the PI3K-mTOR signaling pathway using molecules such as rapamycin. Rapamycin successfully reduced cognitive impairment and social behavior deficit in mouse models of tuberous sclerosis [61] [62] [63] and improved behavior in adult mice with a deletion of PTEN 64 . Unexpectedly, even gross anatomical abnormalities such as neuronal hypertrophy were reversed at the adult stage 64 . In patients with tuberous sclerosis, rapamycin led to a marked reduction in the volume of astrocytomas and in seizure frequency, suggesting that this might be an alternative therapy to neurosurgical resection that could increase the quality of life for patients 65 . However, the efficacy of rapamycin in ameliorating behavioral abnormalities, including those that are regarded as ASD core symptoms, remains to be further investigated, and the possibility of adverse events occurring in patients receiving such treatments also remains to be determined 66 .
The second strategy is repression of mRNA translation by inhibiting the action of the group 1 metabotropic glutamate receptors mGluR1 and mGluR5. A 50% reduction in mGluR5 expression decreased excess translation and improved behavior in the fragile X mouse model 42 . The mGluR5 antagonist MPEP (2-methyl-6-(phenylethynyl)pyridine) can rescue altered dendritic spine morphology as well as behavioral and cognitive deficits in different models of fragile X syndrome (reviewed in ref. 67 ). Chronic treatments with CTEP, a high affinity, longacting and orally bioavailable mGluR inhibitor, restored cognitive functions, ameliorated auditory hypersensitivity, aberrant dendritic spine density and overactive extracellular signal-regulated kinase (ERK) and mTOR signaling, and partially corrected the macroorchidism observed in male mouse models of fragile X syndrome 68 .
In humans, a recent randomized, double-blind, crossover study of 30 males with fragile X syndrome-all of them with severe autistic symptoms-was performed to evaluate the effects of the mGluR5 antagonist AFQ056 (ref. 69) . Despite a lack of improvement of the group of patients (n = 30) as a whole, secondary analysis revealed that a subset of patients with a fully methylated FMR1 gene (n = 7) showed a benefit as measured with the aberrant behavior checklist (mean decrease −27.8 in patients with full methylation versus +3.2 in patients with partial methylation), highlighting the importance of identifying relevant biomarkers to assess therapeutic benefits. Three different mGluR5 antagonists, AFQ056 (Novartis), RO4917523 (Hoffmann-La Roche) and STX107 (Seaside Therapeutics) are currently being investigated in advanced clinical trials (phases 2-3) or will start to be investigated shortly. Studies in mice suggest that mGluR antagonists could also be efficacious for treating other synaptic defects. MPEP can reduce self-grooming behavior in BTBR mice, an inbred genetic mouse model of ASD 70 . Nlgn3 knockout mice show ectopic synapse formation and perturbed mGluR-dependent synaptic plasticity, a hallmark of fragile X syndrome. These phenotypes could be rescued by reexpression of Nlgn3 in juvenile mice, again highlighting the possibility of reverting neuronal circuit alterations in autism after the completion of development 71 . Lovastatin, an inhibitor of ERK-mediated protein synthesis currently used in treatment of hypercholesterolemia, has recently been shown to reduce audiogenic seizures in a mouse model of fragile X 72 . Finally, minocycline, a broad-spectrum tetracycline antibiotic, also represses mRNA translation 48 . In fragile X mice, treatment with minocycline for 1 month after birth normalized the dendritic spine defects and improved behavior and cognition. In addition, the number of ultrasonic vocalizations of males in the presence of estrus females was restored to that of wild-type mice 73 . Two open trials of minocycline in patients with fragile X syndrome demonstrated significant improvements, advocating for placebo-controlled trials of this drug 74, 75 .
A second pathway in ASD that could be modulated by drugs concerns the synaptic excitation-inhibition balance. Several genes associated with ASD seem to be involved in the formation of excitatory and inhibitory synapses, such as those encoding neuroligins and neurexins. In addition, mutations in genes associated with epilepsy, such as SCN1A, which encodes a voltage-gated sodium channel, have been found in patients with ASD 76 . In mice haploinsufficient for Scn1a, treatment with low-dose clonazepam, a positive allosteric modulator of GABA A receptors, completely reversed the abnormal social behaviors and deficits in fear memory 77 . Activation of the GABA B receptor by arbaclofen decreased mRNA translation in the cortex of fragile X mice and corrected the increased spine density 78 . In humans, a recent randomized, double-blind, placebo-controlled crossover study using arbaclofen in 63 subjects with a full mutation in the FMR1 gene showed a slight improvement of social abilities measured by the aberrant behavior checklist social avoidance subscale but no significant benefit in the primary outcome measures quantified by the aberrant behavior checklist irritability subscale 79 . Another example is provided by the Nlgn1 knockout mouse, which shows a reduced NMDA/AMPA ratio at corticostriatal synapses 52 . In these mice, administration of the NMDA receptor (NMDAR) partial co-agonist d-cycloserine rescued the repetitive grooming phenotype. In Shank2 knockout mice, direct stimulation of NMDARs with d-cycloserine normalized NMDAR function and improved social interaction 51 . Recently, an alternative and interesting new strategy to modulate the excitation-inhibition balance emerged that used the diuretic chloride-transporter antagonist bumetanide, which reduces intracellular chloride concentration, reinforcing GABAergic inhibition. A recent clinical trial in patients with ASD showed improvements calling for larger-scale randomized trials to test this drug 80 .
Environmental and social enrichment strategies. Finally, environmental enrichment has been used to reverse abnormal phenotypes in mouse models of ASD. Changing objects and adding a running wheel in the cage decreased anxiety and restored dendritic length and branching, spine density and maturation in a mouse model of fragile X 33 . The same strategy has been extensively used in mouse models of Rett syndrome and has restored locomotor activity, improved learning deficits and anxiety and increased BDNF expression 81 . Another strategy that might hold promise is social enrichment. Housing BTBR mice with highly social C57BL/6 mice has been reported to enhance the social interactions in the BTBR strain 82 . A combination of both social and physical enrichment rescued motor defects, improved npg p e r s p e c t i v e nature medicine VOLUME 19 | NUMBER 6 | JUNE 2013learning and memory, reduced aggressive behavior and relieved anxiety in a mouse model of Potocki-Lupski syndrome. This clinical syndrome is caused by a 3.7-Mb duplication in chromosome 17p11.2 and is characterized by neurobehavioral abnormalities, intellectual disability and ASD in 70-90% of affected individuals 83 . Interestingly, in the mouse model study, social enrichment was shown to increase stereotypic repetitive behavior in both mutant and wild-type mice, suggesting that the repetitive behavior tested (i.e. nose pokes) is sensitive to sensory and social overstimulation even in wild-type mice. To our knowledge, no studies have tested 'behavioral strategies' , that is, task repetition and regular training through repeated exposure with highly social strains as demonstrators or initiators, to improve the behavior of mutant mice in social interaction tasks. It would be interesting to test whether such behavioral interventions, which have demonstrated their efficacy in patients with ASD 84 , could positively affect the behavior of mouse models of ASD.
Taken together, these results indicate that some synaptic and behavioral defects can be restored in adult mice even after the end of the critical periods of development. Nevertheless, some points remain to be further investigated. Many of these studies were performed on one genetic background, with small groups of mice per treatment, in some cases only in males (details in Supplementary Table 1) . The stability of the improvement and the side effects of the treatments were not always documented. It was also shown that the behavioral consequence of a mutation might also be different across generations 85 or on different backgrounds 86 . The investigation and publication of possible worsening of phenotypes in mouse models should also be encouraged to complement knowledge about treatments and dose effects 87 . Finally, none of these studies investigated a combination of pharmacological intervention and a modified (enriched) environment to test for potential optimization of treatment. The key questions now are whether the positive results obtained in rodents can be translated to humans and how best to design trials to test therapeutic modalities that have shown promise in animal models of ASD.
Future directions for clinical trials
Only two drugs, risperidone and aripiprazole, have been approved by the US Food and Drug Administration for the treatment of ASD. Although these drugs serve to manage challenging and repetitive behaviors, they have little effect on the social communication deficit observed in ASD 88 . Developing knowledge-based treatments for ASD will have to take into account the high genetic and clinical heterogeneity of these conditions 89 . To date, the most frequently mutated genes affect less than 0.1-1% of the affected subjects, that is, approximately 8,000-80,000 individuals in all G8 countries. Standard randomized placebo-controlled clinical trials in hundreds of patients will therefore be difficult to achieve for ASD, and specific clinical trials designed for rare diseases need to be devised 90 .
One of the main challenges for clinical trials in ASD is the considerable degree of heterogeneity, which could mask the effects of the tested treatment. Furthermore, the clinical scores most frequently used to measure treatment efficacy in clinical trials might be too focused on the core ASD symptoms and do not necessarily reflect improvements in quality of life 91 . For example, most of the pharmacological trials for ASD in ClinicalTrials.gov (n = 153) are using the clinical global impression scale (33%), which measures clinical improvement, and the aberrant behavior checklist (31%), which measures the comorbid problem behaviors associated with ASD. Both instruments do not take into account the quality of life of patients, and an improvement measured by these instruments does not always correlate with better functioning in everyday life 92 . Therefore, one possibility would be to have quality-of-life scales as the primary outcome scales and autism checklists as the secondary ones. Or, when designing new studies, researchers could flag from the beginning that both types of scales should be preset as the (combined) primary outcome variable.
We propose that three major steps are needed to improve the efficacy of clinical trials for patients with ASD and synaptic defects ( Fig. 3) : (i) obtain more homogenous subgroups of individuals with ASD, as determined on the basis of the affected genes or pathways npg p e r s p e c t i v e rather than on the clinical phenotype; (ii) identify relevant clinical outcomes and biomarkers related to these subgroups (for example, neuronal, biochemical and brain imaging markers); and (iii) increase knowledge of the natural history of this subgroup of patients to identify, for example, periods of symptoms worsening. The benefit of a clinical trial strategy focused on patients selected for their synaptic defects is to reduce the genetic, but also the phenotypic, heterogeneity. The strategy of selecting patients on the basis of the affected genes or pathways is currently used for 'syndromic' forms of ASD, such as tuberous sclerosis and fragile X syndrome. Using the same strategy, specific synaptic clinical trials should now be launched for ASD. As a first step, patients enrolled in these synaptic clinical trials should be selected using whole-genome sequencing to identify the causative or contributory synaptic mutations as well as putative modifier genes. In many cases, patients with inherited deletions of 16p or de novo SHANK2 mutations, for example, carry additional mutations, and the presence of multiple hits might be indeed the rule rather than the exception in ASD 93, 94 . A better knowledge of these modifier genes will inform clinicians and researchers on responses to treatment. For example, the identification of multiple genetic hits in a patient might explain why he or she will not fully respond to the treatment whereas other patients without these additional genetic mutations will.
Animal models and patient-specific induced pluripotent stem cells (iPSCs) should be used to inform researchers on the synaptic defects present in each patient and thereby enable them to enroll patients with different causative mutations but with apparently similar synaptic defects (for example, decreased or increased synaptic density, excitation-inhibition imbalance) in the clinical trials. Specific neural cell subtypes differentiated from patient-specific iPSCs are likely to be a powerful tool for evaluating the hierarchy of cellular vulnerability in these diseases and the potential efficacy of therapies being tested. As an example, a specific assay for dysfunction of synaptic proteins, such as SHANK, remains to be determined. Cellular models expressing deleterious SHANK3 mutations suggest that modifications of dendritic spine morphology via an actin-dependent mechanism are part of the mutant phenotype 26 . Similarly, SHANK3 mutant mice show a hypertrophy of medium spiny neurons with an increase in the complexity of dendritic arbors and total dendritic length 17, 18 . An in-depth characterization of the synaptic defect associated with each type of genetic mutation is crucial for two main reasons: first, the identification of a robust readout is necessary for drug screening; second, patients with mutations in similar genes might actually show the opposite synaptic defects, as observed in Shank2 (increased NMDA) and Shank3 (decreased NMDA) knockout mice 17, 18, 51 . If these results are confirmed in iPSCs from patients with these mutations, then patients with SHANK2 and SHANK3 mutations should be enrolled in two different synaptic clinical trials to test potential disease-modifying therapies.
Finally, a better knowledge on the natural history of each subgroup of patients is crucial for designing a synaptic clinical trial. For example, most patients with de novo or truncating mutations in SHANK3 show an early regression before 36 months and a worsening during adolescence, which correlates with a frequent emergence of epilepsy 95 . SHANK3 mutations have also been identified in individuals developing adult-onset SHANK3 related-disorders, such as schizophrenia and bipolar disorders 96, 97 . To better understand this variability in clinical outcome and trajectories of the patients, large-scale initiatives are currently ongoing. The Simons Variation in Individuals Project (Simons VIP) aims to identify and study a large number of individuals with a deletion or duplication of chromosome 16p11.2 that increases the risk of developing neurodevelopmental disorders 98 . The Rett Rare Disease Clinical Research Center natural history study has enrolled more than 800 patients and led to a redefinition of the critical periods of deterioration of patients and the emergence of ritualized and stereotypic behaviors 99 . These careful analyses of genetically defined ASD subtypes should allow detailed phenotypic comparisons within and among these groups to clarify genotype-phenotype correlations.
Recruiting the functional allele: a possible ASD therapy? The proposed strategy of synaptic clinical trials for ASD should lead to personalized treatments by taking into account the genetic synaptic defect present in the patient. In this line, the observation that abnormal gene dosage (deletion or duplication) seems to play a key part in ASD could be an advantage for finding new treatments 2 . In contrast to X-linked or autosomal recessive traits, for which the gene product is often absent, in most patients with ASD for which a genetic cause is known, only one allele is affected by copy number variations or two alleles carry weak mutations but are still functional 100 . Given these observations, one promising route for treatment is to activate the expression of the remaining functional allele (in the case of a deletion) or to slightly repress the expression of the gene (in the case of a duplication). This strategy was recently used for Angelman's syndrome, a disorder affecting an imprinted genomic region on chromosome 15q11-q13 that is caused by deletion or mutation of the maternal allele of UBE3A. Using an unbiased screen in primary cortical neurons from mice, Huang et al. 101 identified several topoisomerase inhibitors that unsilence the paternal allele of UBE3A. Such molecules could therefore reactivate the functional, but dormant, allele of UBE3A in patients with Angelman's syndrome. More generally, the amount of synaptic proteins is regulated by transcription 102 , splicing 103 , mRNA transport 104 , translation 105 and degradation 106 . A better knowledge of the factors that regulate each of these regulatory steps might help to identify new targets for restoring the amount of specific synaptic proteins in patients. In addition, given that several genes associated with ASD are regulated by neuronal activity 20 , it is most likely that a combination of pharmacological treatments (that restore the amount of synaptic proteins) and behavioral treatments (that stimulate specific neuronal circuits) might show the most benefit for patients.
Conclusions
There is increasing support for the notion that customized treatments could lead to recovery in some patients with ASD, which may spur revision of views on the stability of ASD phenotypes. In addition, further in-depth molecular pathophysiological characterization of ASDs that are not directly linked to synaptic dysfunction (for example, defects in chromatin remodeling 107 or metabolism 108 ) should be carried out to investigate the possibility of reversing phenotypes. An integrated approach, which brings together cellular and animal models and knowledge-based clinical trials, will be key to furthering understanding of which affected genes and pathways in ASD can be efficiently recovered and will also provide a basis for developing new therapies. p e r s p e c t i v e
